Canada markets closed

bioMérieux S.A. (BMXMF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
120.10+0.10 (+0.08%)
At close: 09:30AM EST
Full screen
Trade prices are not sourced from all markets
Previous Close120.00
BidN/A x N/A
AskN/A x N/A
Day's Range120.10 - 120.10
52 Week Range105.65 - 158.75
Avg. Volume172
Market Cap14.196B
Beta (5Y Monthly)-0.23
PE Ratio (TTM)24.59
EPS (TTM)4.88
Earnings DateN/A
Forward Dividend & Yield0.76 (0.63%)
Ex-Dividend DateJun. 04, 2021
1y Target EstN/A
  • Business Wire

    Baxter and bioMérieux Announce CE Mark for NEPHROCLEAR™ CCL14 Test to Predict Persistent Severe Acute Kidney Injury

    DEERFIELD, Ill. & MARCY L’ETOILE, France, October 21, 2021--Baxter International Inc. (NYSE:BAX), a global leader in acute care, and bioMérieux (EPA:BIM), a global leader in in vitro diagnostics, today announced the CE marking of the NEPHROCLEAR™ CCL14 Test. The NEPHROCLEAR™ CCL14 Test is designed to predict persistent severe acute kidney injury (PS-AKI) and can be used to support timely clinical decision-making and care pathways. The companies intend to commercially launch the NEPHROCLEAR™ CCL1


    bioMerieux to Exhibit at SupplySide West 2021 at Mandalay Bay in Las Vegas Oct. 25-28, 2021

    bioMérieux to Showcase its Full Suite of Nutraceutical Testing Solutions, Including the Recently Released GENE-UP® NUTRAPLEX PRO™ AssayCHICAGO, IL / ACCESSWIRE / October 5, 2021 / bioMérieux, a world leader in the field of in vitro diagnostics, will exhibit at SupplySide West 2021, the leading trade show for health and nutrition industry professionals focused on dietary supplements, beverages, functional foods, personal care, and sports nutrition innovation. SupplySide West 2021 will take place

  • Zacks

    BIOMERIEUX (BMXMF) Upgraded to Buy: What Does It Mean for the Stock?

    BIOMERIEUX (BMXMF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.